Patents by Inventor Arnold Bayer

Arnold Bayer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-infective hydroxy-phenyl-benzoates and methods of use
    Patent number: 8809263
    Abstract: The invention provides a method for preventing or treating a disease caused by an extracellular microorganism, said method comprising systemically administering to a subject in need thereof a prophylactically or therapeutically effective amount of a salicylic acid (SAL) or a SAL analogue. The extracellular microorganism can be of the bacterial genus Staphylococcus, for example, Staphylococcus aureus. The extracellular microorganism can be a strain that is resistant to at least one antibiotic. The strain can be selected from the group consisting of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA).
    Type: Grant
    Filed: October 26, 2009
    Date of Patent: August 19, 2014
    Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: Michael Yeaman, Arnold Bayer
  • ANTI-INFECTIVE HYDROXY-PHENYL-BENZOATES AND METHODS OF USE
    Publication number: 20120040888
    Abstract: The invention provides a method for preventing or treating a disease caused by an extracellular microorganism, said method comprising systemically administering to a subject in need thereof a prophylactically or therapeutically effective amount of a salicylic acid (SAL) or a SAL analogue. The extracellular microorganism can be of the bacterial genus Staphylococcus, for example, Staphylococcus aureus. The extracellular microorganism can be a strain that is resistant to at least one antibiotic. The strain can be selected from the group consisting of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA).
    Type: Application
    Filed: October 26, 2009
    Publication date: February 16, 2012
    Applicant: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
    Inventors: Michael R. Yeaman, Arnold Bayer